BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

On November 18, 2026 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, reported that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA (motixafortide) to Soleus Capital Management, L.P. and its affiliates ("Soleus") for a one-time payment of $5.6 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Soleus will acquire BioLineRx’s 14.4% royalty interest in future net sales of APHEXDA under the Company’s existing license agreement with Ayrmid Pharma Ltd. ("Ayrmid"). The transaction excludes the remaining 3.6% royalty interest attributable to the original licensor of motixafortide to BioLineRx, which will continue to retain its interest in the royalty stream. BioLineRx has retained its rights to receive potential commercial milestone payments under the Ayrmid agreement, as well as royalty payments attributable to periods prior to the closing of the transaction.

"This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments," said Philip Serlin, Chief Executive Officer of BioLineRx. "Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for our company and our shareholders."

"We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA," said Benjamin Lund, Partner at Soleus Capital. "We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement."

BioLineRx intends to use the proceeds to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with the partial loan repayment, the Company’s minimum cash balance requirement under the loan agreement (currently $4 million) will be eliminated. The transaction is expected to close on or about November 30, 2026.

About APHEXDA (motixafortide)
APHEXDA is a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma. APHEXDA is being commercialized by Ayrmid globally, except in Asia, where it is partnered with Gloria Biosciences.

(Press release, BioLineRx, NOV 18, 2026, View Source [SID1234674918])

Immunome to Present at Upcoming Investor Conferences

On November 18, 2026 Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, reported that members of the company’s management team will present at the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

9th Annual Evercore Healthcare Conference

Presentation Date/Time: December 1, 2026, at 9:10 a.m. ET

Piper Sandler 38th Annual Healthcare Conference

Presentation Date/Time: December 2, 2026, at 10:30 a.m. ET

Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.immunome.com. Replay webcasts will be available for approximately 30 days following the live presentations.

(Press release, Immunome, NOV 18, 2026, View Source [SID1234674934])

Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer

On November 18, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported new preclinical data demonstrating the potential of atebimetinib to serve as a backbone for combinations with multiple classes of anticancer agents. The findings, generated using both animal models and three-dimensional (3D) tumor models of pancreatic ductal adenocarcinoma (PDAC), identify multiple synergistic combination strategies and provide further support for atebimetinib’s potential to play a central role as a MAPK pathway backbone for combinations in pancreatic cancer and beyond. The data will be presented in a Poster Spotlight presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe atebimetinib’s long survival, excellent tolerability profile, and broad all-comers activity reported in Phase 2 make it the increasingly likely backbone of choice for combinations with both chemotherapies and emerging agents that target subsets of pancreatic cancer patients," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Building on our recently announced collaboration targeting CLDN18.2-positive pancreatic cancer, these new findings demonstrate synergistic activity with multiple classes of emerging agents including PRMT5 inhibitors for tumors with MTAP deletions, as well as KRAS G12D and G12V inhibitors for tumors with those particular mutations. The data presented today strengthen the scientific rationale for developing atebimetinib as a backbone therapy in combination with additional agents targeting patient subsets in pancreatic cancer and suggest a broad set of potential opportunities to deploy atebimetinib in multiple combinations across multiple lines of therapy, starting with the exciting chemotherapy combination we are evaluating in our Phase 3 study, MAPKeeper 301."

The research being presented today includes results from Immuneering’s humanized 3D tumor growth assay (3D-TGA) platform, which previously identified the potential for atebimetinib to enhance the activity of gemcitabine and nab-paclitaxel (GnP), a combination subsequently supported by encouraging clinical results in the Company’s Phase 2a study in first-line pancreatic cancer. This combination is now being evaluated in MAPKeeper 301, a phase 3 pivotal trial evaluating atebimetinib plus mGnP versus GnP.

Key findings include:

Broad synergy with targeted therapies: Atebimetinib demonstrated synergistic activity in preclinical PDAC models when combined with multiple mutation-specific KRAS inhibitors targeting KRAS G12C, G12D, and G12V, PRMT5 inhibitors, as well as agents targeting BRAF, EGFR, and other components of the MAPK signaling pathway.
In vivo validation of KRAS inhibitor combinations: Combination activity with a KRAS G12D-targeted agent was confirmed in an in vivo pancreatic cancer xenograft model, providing additional evidence of atebimetinib’s potential to enhance the activity of mutant-selective RAS-targeted therapies.
Activity with complementary cancer treatment mechanisms: Atebimetinib demonstrated promising combination activity with agents targeting pathways involved in cancer cell survival, proliferation, and resistance, including GSK-3β, PI3K/mTOR, CDK4/6, and other targets, as well as multiple chemotherapy agents.
Biomarker-driven treatment opportunities: Combination activity was particularly pronounced in models with specific genomic characteristics, including matching KRAS mutations for vertical pathway inhibition and MTAP deletion for combinations involving PRMT5 inhibitors. These findings support the potential for atebimetinib to serve as a broad, all-comers MAPK backbone combined with specific agents targeted at particular patient populations.
Potential utility across multiple lines of therapy: The results support a proposed treatment strategy in which atebimetinib could be deployed in combination with chemotherapy in the first-line setting, potentially combined with mutant-selective RAS inhibitors in subsequent treatment, and paired with biomarker-selected therapies following RAS inhibitor exposure.

Presentation Details:
Title: Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma.
Abstract Number: 22
Poster Number: PB-003
Presenter: Anna Travesa
Date: Thursday, November 19, 2026

The poster is available on the publications section of Immuneering’s website.

(Press release, Immuneering, NOV 18, 2026, View Source [SID1234674919])

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer

On November 18, 2026 Summit Therapeutics Inc. (NASDAQ: SMMT) reported the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC). The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Consolidation therapy, given after a patient has responded to initial treatment, aims to deepen or prolong that response and delay or prevent the cancer from coming back or progressing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HARMONi-10 is Summit’s sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC, following HARMONi, HARMONi-3, and HARMONi-7. The study extends Summit’s global clinical development program into the locally advanced, unresectable setting, where durvalumab, following curative-intent chemoradiation, is a current standard of care.

"HARMONi-10 is the next bold step in a clinical development program built to change what is possible for people with lung cancer," said Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit. "We are taking ivonescimab head-to-head against standard-of-care PD-L1 therapy in this global Phase III trial, in earlier stage disease, because we believe in its potential and intend to prove it. This is the rigor, ambition, and conviction we have brought to this program from day one."

HARMONi-10 is a multi-regional, open-label, potentially registration-enabling Phase III clinical trial. The primary endpoint of the study is progression-free survival (PFS). Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026.

"Patients with unresectable Stage III non-small cell lung cancer endure an intensive course of chemoradiation, and too often their disease still progresses thereafter despite current consolidation therapy," said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit. "In this curative-intent setting, this is a gap we are determined to close. With PD-1 and VEGF blockade in a single molecule, we believe ivonescimab has the potential to keep the disease from progressing for longer than durvalumab in this setting. We are moving with urgency to activate sites globally and bring ivonescimab to many more people living with lung cancer."

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally, and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 18 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, six of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC (HARMONi, HARMONi-3, HARMONi-7) and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC; HARMONi-GI3) and urothelial carcinoma (bladder cancer; HARMONi-GU1). The two cooperative studies are in head and neck squamous cell carcinoma (HNSCC; ILLUMINE) and biliary tract cancer (BTC; EA2251). Summit announced the initiation of an additional Phase III trial in NSCLC, HARMONi-10, in November 2026.

HARMONi is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR TKI (e.g., osimertinib).

HARMONi-3 is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous or non-squamous NSCLC, irrespective of PD-L1 expression. The clinical trial is evaluating the two histologies as individual, separately powered cohorts with independent statistical powering.

HARMONi-7 is a Phase III clinical trial evaluating ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

HARMONi-10 is a Phase III clinical trial evaluating ivonescimab compared to durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy.

Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC and one is in BTC. In addition to Summit’s positive HARMONi study in NSCLC, Akeso has had positive read-outs in four single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, HARMONi-6 (each in NSCLC), and HARMONi-GI1 (in BTC) for ivonescimab, including a statistically significant overall survival benefit in all four studies from China.

Akeso is actively conducting multiple Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

(Press release, Summit Therapeutics, NOV 18, 2026, View Source [SID1234674935])

Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045

On November 18, 2026 Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor, reported that the United States Patent and Trademark Office ("USPTO") has granted a U.S. patent covering stenoparib treatment regimens. The patent is to provide protection for the claimed methods into 2045.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity’s clinical development program. They also encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.

"The commercial significance of this patent is enormous. Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials," said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. "A protection period extending into 2045 strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions as we generate the clinical data needed to support FDA approval".

The patent complements Allarity’s previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. Together, these patents enable the Company’s strategy to develop stenoparib alongside a proprietary approach to identifying patients most likely to benefit.

The patent, titled Methods for Treating Cancer, has been assigned U.S. Patent No. 12,806,205 and arises from U.S. Patent Application No. 18/606,590.

(Press release, Allarity Therapeutics, NOV 18, 2026, View Source [SID1234674920])